(Reuters) – Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

The successful completion of the trial paves the way for Revance to submit its application for marketing approval of the drug in the first half of 2019, the company said.

More than 95 percent of patients administered with the company’s long-acting neuromodulator injection RT002 were found to have

Read More At Article Source | Article Attribution